Advertisement

LO SCALPELLO-OTODI Educational

, Volume 33, Issue 3, pp 207–212 | Cite as

La viscosupplementazione nei pazienti emofilici

  • Francesco Falez
  • Filippo La CavaEmail author
  • Luigi Ciolli
  • Alessandro Ciompi
Aggiornamenti
  • 15 Downloads

Viscosupplementation in haemophilic patients

Abstract

We evaluated the results obtained from the treatment of 88 intraarticular hyaluronic acid injections in haemophilic arthropathy according to the parameters of pain, function, health and radiographic evaluation. In 58 joints there was an improvement in the conditions preceding the treatments, in 20 the joint disease was stabilised, in 10 the treatment was ineffective and 9 of these were subsequently operated. 36 patients repeated the cycle at a distance. No adverse effects. Haemophilic arthropathy in its mild or moderate forms of joint damage can be effectively treated with viscosupplementation.

Notes

Ringraziamenti

Si ringraziano la Dottoressa Cristina Santoro e le sue collaboratrici (U.O.S. Diagnosi Speciale e Terapia dell’Emostasi e della Trombosi, U.O.C. Ematologia, Sezione Ematologia del Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma) e il consulente ortopedico presso quella sede, Dottoressa Luana Poggini.

Conflitto di interesse

Gli autori Francesco Falez, Filippo La Cava, Luigi Ciolli e Alessandro Ciompi dichiarano di non avere alcun conflitto di interesse.

Consenso informato e conformità agli standard etici

Tutte le procedure descritte nello studio e che hanno coinvolto esseri umani sono state attuate in conformità alle norme etiche stabilite dalla dichiarazione di Helsinki del 1975 e successive modifiche. Il consenso informato è stato ottenuto da tutti i pazienti inclusi nello studio.

Human and Animal Rights

L’articolo non contiene alcuno studio eseguito su esseri umani e su animali da parte degli autori.

Bibliografia

  1. 1.
    Mannucci PM (2008) Back to the future: a recent history of haemophilia treatment. Haemophilia. Suppl. 14(3):10–18 CrossRefGoogle Scholar
  2. 2.
    Eandi M, Pradelli L, Povero M (2013) Costi della terapia dell’emofilia A in Italia: confronto dell’uso di FVIII plasmaderivato e ricombinante mediante un modello di simulazione ad eventi discreti (DES). Farmeconomia. Health Econ Ther Pathw 14(2):51–74 Google Scholar
  3. 3.
    Roosendaal G, Vianen ME, Wenting MJ et al. (1998) Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Jt Surg Br 80(3):540–545 CrossRefGoogle Scholar
  4. 4.
    Srivastava A, Brewer AK, Mauser-Bunschoten EP (2013) Guidelines for the management of hemophilia. Haemophilia 19:1–47 CrossRefGoogle Scholar
  5. 5.
    Wang CT, Lin YT, Chiang BL et al. (2006) High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthr Cartil 14(12):1237–1247 CrossRefGoogle Scholar
  6. 6.
    Belmonte C, Pozo MA, Balazs EA (1998) In: Proceedings of the Wenner-Gren foundation international symposium. Portland, London, pp 205–217 Google Scholar
  7. 7.
    Moore AR, Willoughby DA (1995) Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 17:153–156 PubMedGoogle Scholar
  8. 8.
    Bagga H, Burkhardt D, Sambrook P, March L (2006) Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 33:946–950 PubMedGoogle Scholar
  9. 9.
    Waddell DD, Cefalu CA, Bricker DC (2003) An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis. Curr Med Res Opin 19:499–507 CrossRefGoogle Scholar
  10. 10.
    Marino AA, Waddell DD, Kolomytkin OV (2004) Increased intercellular communication through gap junctions may contribute to progression of osteoarthritis. Clin Orthop Relat Res 422:224–232 CrossRefGoogle Scholar
  11. 11.
    Takahashi K, Hashimoto S, Kubo T et al. (2000) Effect of hyaluronan on chondrocytes apoptosis and nitric oxide production in experimentally induced ostheoarthritis. J Rheumatol 27(7):1713–1720 PubMedGoogle Scholar
  12. 12.
    Hooiveld M, Roosendaal G, Wenting M et al. (2003) Short-term exposure of cartilage to blood results in chondrocyte apoptosis. Am J Pathol 162(3):943–951 CrossRefGoogle Scholar
  13. 13.
    Uebelhart D, Williams JM (1999) Effects of hyaluronic acid on cartilage degradation. Curr Opin Rheumatol 11(5):427–435 CrossRefGoogle Scholar
  14. 14.
    Creamer P, Sharif M, George E et al. (1994) Intra-articular hyaluronic acid in ostheoarthritis of the knee: an investigation into mechanisms of action. Osteoarthr Cartil 2(2):133–140 CrossRefGoogle Scholar
  15. 15.
    Balazs EA, Denlinger JL (1993) Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 39:3–9 PubMedGoogle Scholar
  16. 16.
    Langworthy MJ, Saad A, Langworthy NM (2010) Conservative treatment modalities and outcomes for osteoarthritis: the concomitant pyramid of treatment. Phys Sports Med 38:133–145 CrossRefGoogle Scholar
  17. 17.
    Moskowitz RW, Nuki G, Abramson S et al. (2008) OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16(2):137–162 CrossRefGoogle Scholar
  18. 18.
    Gilbert MS (1993) Prophylaxis: musculoskeletal evaluation. Semin Hematol 30:3–6 PubMedGoogle Scholar
  19. 19.
    Innocenti M, Civinini R, Villano M et al. (2006) La viscosupplementazione nel trattamento dell’artropatia emofilica. GIOT 32:2215–2221 Google Scholar
  20. 20.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care 6(30):473–483 CrossRefGoogle Scholar
  21. 21.
    Arnold WD, Hilgartner MW (1977) Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Jt Surg 59(3):287–305 CrossRefGoogle Scholar
  22. 22.
    Bellamy N, Campbell J, Welch V et al (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006:CD005321 Google Scholar
  23. 23.
    Dixon AS, Jacoby RK, Berry H, Hamilton EB (1988) Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin 11(4):205–213 CrossRefGoogle Scholar
  24. 24.
    Mehraban F, Lark MW, Ahmed FN et al. (1998) Increased secretion and activity of matrix metalloproteinase- 3 in synovial tissues and chondrocytes from experimental osteoarthritis. Osteoarthr Cartil 6:286–294 CrossRefGoogle Scholar
  25. 25.
    Tetlow LC, Adlam DJ, Woolley DE (2001) Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 44:585–594 CrossRefGoogle Scholar
  26. 26.
    Rodriguez-Merchan EC (2012) Intra-articular injections of hyaluronic acid (viscosupplementation) in the haemophilic knee. Blood Coagul Fibrinolysis 23(7):580–583 CrossRefGoogle Scholar
  27. 27.
    Carulli C, Civinini R, Martini C et al. (2011) Viscosupplementation in haemophilic arthropathy: a long-term follow-up study. Haemophilia 18(3):210–214 CrossRefGoogle Scholar
  28. 28.
    Ghosh P, Guidolin D (2002) Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 32(1):10–37 CrossRefGoogle Scholar

Copyright information

© Società Italiana Ortopedici Traumatologi Ospedalieri d’Italia 2019

Authors and Affiliations

  • Francesco Falez
    • 1
    • 2
    • 3
  • Filippo La Cava
    • 3
    Email author
  • Luigi Ciolli
    • 3
  • Alessandro Ciompi
    • 3
  1. 1.Area Interdipartimentale OrtopedicaASL Roma1RomaItalia
  2. 2.UOC Ortopedia e TraumatologiaOspedale San Filippo NeriRomaItalia
  3. 3.UOC Ortopedia e TraumatologiaOspedale Santo SpiritoRomaItalia

Personalised recommendations